Skip to content
Screener

Geron GERN Noncurrent liability related to sale of future royalties

Noncurrent liability related to sale of future royalties at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$562.57M+3.9%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$100M0.0%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+43.9%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+43.9%
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
$3.28M-25.7%
Zymeworks logo
ZymeworksZYME
$252.63M

Other financials

Income statement

See full
Revenue$57.5M+17.2%
Operating income-$12.5M-0.3%
Net income-$16.7M-1.9%
EPS (diluted)-$0.020.0%

Balance sheet

See full
Cash & equivalents$64.5M-18.9%
Total debt$134.1M-0.3%
Total equity$218.6M-15.8%
Total assets$519.0M-6.5%

Cash flow

See full
Operating cash flow-$15.8M+42.3%
CapEx$206.0K+2.0%
Free cash flow-$43.8M-6.8%

Valuation

See full
Market cap$1.01B+13.8%
Enterprise value$1.08B+14.5%
P/S4.9×-180×

Profitability

See full
Operating margin-705.5%-351pp
Net margin-682.5%-339pp
FCF margin-734.4%-365pp

Returns & leverage

See full
Return on equity-28.3%-2.3pp
Debt / equity0.6×+0.1×
Current ratio6.9×-1.0×

Where this comes from

Reported directly by Geron in its filing.

Tagged under the XBRL concept gern:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent.

The source filing: Geron’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:41 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886744-26-000037
Line itemJUNE 30,2026DECEMBER 31,2025
Accrued liabilities30,71551,340
Total current liabilities70,331111,542
Noncurrent operating lease liabilities1,0001,445
Noncurrent liability related to sale of future royalties108,933112,134
Noncurrent debt120,131119,547
Total liabilities300,395344,668
Commitments and contingencies
Stockholders' equity:

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Geron's noncurrent liability related to sale of future royalties?
Geron (GERN) reported noncurrent liability related to sale of future royalties of $108.93M in Q2 2026.
How has Geron's noncurrent liability related to sale of future royalties changed year-over-year?
Geron's noncurrent liability related to sale of future royalties decreased by 1.4% year-over-year, from $110.53M to $108.93M.
What does noncurrent liability related to sale of future royalties mean?
Noncurrent liability related to sale of future royalties as reported by Geron Corp.

Ask your AI about Geron's noncurrent liability related to sale of future royalties.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude